The document discusses THC (tetrahydrocannabinol), the main psychoactive compound in marijuana. It describes THC's effects on the brain and body, including euphoria and increased heart rate. It also lists pharmaceutical drugs that contain THC or activate the body's cannabinoid receptors in different ways to treat conditions like nausea, pain, and obesity. The document concludes by outlining a TOXI-LAB procedure for extracting and detecting THC and its metabolites in urine samples.
The document discusses THC (tetrahydrocannabinol), the main psychoactive compound in marijuana. It describes THC's effects on the brain and body, including euphoria and increased heart rate. It also lists pharmaceutical drugs that contain THC or activate the body's cannabinoid receptors in different ways to treat conditions like nausea, pain, and obesity. The document concludes by outlining a TOXI-LAB procedure for extracting and detecting THC and its metabolites in urine samples.
The document discusses THC (tetrahydrocannabinol), the main psychoactive compound in marijuana. It describes THC's effects on the brain and body, including euphoria and increased heart rate. It also lists pharmaceutical drugs that contain THC or activate the body's cannabinoid receptors in different ways to treat conditions like nausea, pain, and obesity. The document concludes by outlining a TOXI-LAB procedure for extracting and detecting THC and its metabolites in urine samples.
The document discusses THC (tetrahydrocannabinol), the main psychoactive compound in marijuana. It describes THC's effects on the brain and body, including euphoria and increased heart rate. It also lists pharmaceutical drugs that contain THC or activate the body's cannabinoid receptors in different ways to treat conditions like nausea, pain, and obesity. The document concludes by outlining a TOXI-LAB procedure for extracting and detecting THC and its metabolites in urine samples.
Download as DOCX, PDF, TXT or read online from Scribd
Download as docx, pdf, or txt
You are on page 1of 19
THC Toxic-Lab Test
1.0 DEFINITION OF THC
THC, or tetrahydrocannabinol, is the chemical responsible for most of marijuana's psychological effects. THC changes behavior by binding fitting together like a lock and key to receptors on nerve cells, which then respond with a change in activity.
Figure: Molecule of tetrahydrocannabinol Cannabinoid receptors are concentrated in certain areas of the brain associated with thinking, memory, pleasure, coordination and time perception. There are also cannabinoid receptors on nerves in other parts of the body. THC relieves pain, but it doesn't bind to the same receptors in the brain as opioids such as heroine, morphine and other drugs derived from the poppy plant. THC stimulates cells in the brain to release dopamine, creating euphoria. It also interferes with how information is processed in the hippocampus, which is part of the brain responsible for forming new memories. THC can induce hallucinations, change thinking and cause delusions. These effects of marijuana make it a popular drug, but they also concern mental health advocates. THC can trigger a relapse in schizophrenic symptoms, according to the National Institute on Drug Abuse. THC is one of many compounds found in the resin excreted by glands of the marijuana plant. More of these glands are found around the reproductive organs of the plant
than on any other area of the plant. Other compounds unique to marijuana, called cannabinoids, are present in this resin and may lessen the effect of THC. When THC is exposed to air, it degrades into cannabinol, a cannabinoid which has its own psychological effects. THC concentration also depends on the cultivation of the marijuana plant, known scientifically as Cannabis sativa L. Cannabis that has a minimal amount of THC up to 1 percent is cultivated as hemp. Some strains of Cannabis can have as little as 0.3 percent THC by weight. In other strains, THC makes up 20 percent of the weight in a sample. THC can be extracted from marijuana, or synthesized as is the case for the FDA-approved drug dronabinol.
2.0 EFFECTS OF THC
2.1 Physiological Effects of Marijuana The active ingredient in marijuana is THC. That's short for delta-9- tetrahydrocannabinol. THC is rapidly absorbed after smoking pot. Within minutes, THC and the other substances in marijuana smoke cause short-term medical effects. Signs of using marijuana include: Rapid heart rate Increased blood pressure Increased rate of breathing Red eyes Dry mouth Increased appetite, or "the munchies" Slowed reaction time These effects are reduced after three or four hours. However, marijuana hangs around in your system for as long as a month after smoking. The lingering effects mean you're impaired for several days to weeks after the high wears off.
2.2 Psychological Effects of Marijuana According to the National Institute on Drug Abuse, the main effects of marijuana on mood vary and may include euphoria, calmness, anxiety, or paranoia. Getting high or "stoned" is the reason most pot smokers use marijuana.
2.3 Other short-term psychological effects of pot include: Distorted sense of time Paranoia Magical or "random" thinking Short-term memory loss Anxiety and depression These psychological signs of using pot also generally ease after a few hours. But residual effects can last for days.
2.4 Risks of Marijuana (THC) Use The risks of smoking marijuana go up with heavy use. Although the link has never been proven, many experts believe heavy pot smokers are at increased risk for lung cancer. Heavy marijuana use lowers men's testosterone levels and sperm count and quality. Pot could decrease libido and fertility in some heavy-smoking men. Contrary to what many pot smokers may tell you, marijuana is addictive, at least psychologically. Even among occasional users, one in 12 can feel withdrawal symptoms if they can't get high when they want to. Among heavy pot smokers, the rates of dependence are higher. Many experts also believe that marijuana is physically addictive. Symptoms of withdrawal from pot might include: Aggression Anxiety Depressed mood Decreased appetite
3.0 TYPES OF DRUGS THAT CONTAIN TETRAHYDRACANNABINOL (THC) Pharmaceutical drugs have been developed which either contain or have similar chemicals as those found in the marijuana (cannabis) plant. Some researchers have used their understanding of how the brain processes cannabinoids to develop drugs which follow the same pathways but work differently than marijuana. Pharmaceutical drugs based on marijuana are divided into four categories and listed below with the names, trade names, manufacturers, approval status, suggested medical use and cannabis-related properties. All drugs referenced are in pill form unless otherwise noted (ProCog.org, 2013).
I. Drugs that contain chemicals taken directly from the marijuana plant Name/Trade Name Manufacturer Suggested Medical Use Cannabis-Related Properties Sativex GW Pharmaceuticals Treatment of neuropathic pain and spasticity in patients with Multiple Sclerosis (MS); Analgesic treatment in adult patients with advanced cancer who experience moderate to severe pain. Mouth spray whose chemical compound is derived from natural extracts of the cannabis plant. Sativex contains two cannabinoids: THC (delta-9- tetrahydrocannabinol) and CBD (cannabidiol). II. Drugs that contain synthetic versions of chemicals naturally found in marijuana Name/Trade Name Manufacturer Suggested Medical Use Cannabis-Related Properties Dronabinol/ Marinol Unimed Pharmaceuticals, a subsidiary of Solvay Pharmaceuticals Treatment of nausea and vomiting for patients in cancer treatment; Appetite stimulant for AIDS patients; Analgesic to ease neuropathic pain in multiple sclerosis patients Synthetic Delta-9 THC Dronabinol Metered Dose Inhaler (MDI)/ Marinol aerosol Solvay Pharmaceuticals Treatment of nausea, vomiting, migraines, spasticity in MS patients, and neuropathic pain Human-made THC inhaler III. Drugs that contain chemicals similar to those in marijuana but not found in the plant Name/Trade Name Manufacturer Suggested Medical Use Cannabis-Related Properties Nabilone/ Cesamet Valeant Pharmaceuticals International Treatment of nausea and vomiting in patients undergoing cancer treatment Synthetic cannabinoid similar to THC Dexanabinol Pharmos Neuroprotective for use after cardiac surgery Regain memory and other high-level function following Traumatic Brain Injury (TBI) Synthetic non-psychotropic cannabinoid which blocks NMDA receptors and COX- 2 cytokines and chemokines
CT-3 (ajulemic acid) Atlantic Technology Ventures Treatment of spasticity and neuropathic pain in MS patients Synthetic, more potent analog of THC metabolite THC-11-oic acid PRS- 211,375/ Cannabinor and Cannabinor Oral Pharmos Anti-inflammatory
Treatment of pain Synthetic chemical that specifically binds to the brain's secondary cannabinoid receptor (CB2) HU 308 Pharmos (licensed from the Hebrew University of Jerusalem) Treatment of hypertension Anti-inflammatory Synthetic chemical that specifically binds to the brain's secondary cannabinoid receptor (CB2) HU 331 Cayman Chemical Treatment of memory, weight loss, appetite, neurodegeneration, tumor surveillance, analgesia, and inflammation Synthetic chemical compound composed of central cannabinoid (CB1), peripheral cannabinoid (CB2), and non-CB receptor-mediated pharmacology IV. Drugs that do not work like marijuana but use the same brain pathways Name/Trade Name Manufacturer Suggested Medical Use Cannabis-Related Properties Rimonabant/ Acomplia Sanofi-Aventis Anti-obesity Synthetic chemical that blocks endocannabinoids from being received in the brain, and, as a result, suppresses appetite. Taranabant/ MK-0364 Merck Anti-obesity Targets receptors in the brain linked to appetite. Acts as a Cannabinoid receptor type 1 (CB1R) inverse agonist, blocking cannabinoid receptors in the brain, which suppresses appetite URB597 or KDS-4103 Cayman Chemical and Kadmus Pharmaceuticals Inc Treatment of pain (acute - post- surgical; inflammatory - arthritis; neuropathic - damaged nerve cells from shingles, H.I.V., diabetes), anxiety, and depression Increases the amount of endocannabinoids in the brain by blocking the natural process of deactivating them. The same process that deactivates endocannabinoids also blocks chemicals which regulate mood O-3246 Not available Treatment of spasticity in MS Increases the amount of anandamide, an endocannabinoid,
patients by tricking the brain to produce more instead of uptaking what is already present AM 281 Bachem (formerly Peninsula Laboratories) Neuroprotective for use in association with septic shock Synthetic chemical that blocks the endocannabinoids from being received in the brain, regulating the flow of blood to the brain during septic shock
(ProCog.org, 2013).
4.0 PROCEDURE
TOXI-LAB PROCEDURE In the TOXI-LAB procedure, urine samples were hydrolyzed at room temperature with KOH and then extracted with a mixture of ethyl-acetate and hexane (1:9). The extracts were concentrated onto discs, and those discs were inserted into a toxigram together with a blank toxi disc and a standard disc containing 350ng of 8 -THC-COOH. The plate was then developed using a mixture of heptanes-acetone-glacial acetic acid (70:30:1) and visualized with Fast Blue BB salt. The TOXI-LAB method allowed simultaneous extraction of 10 samples with one control and one standard, using a disposable applicator cartridge. In general, the TOXI-LAB procedure was simple, easy to perform, and required minimal cost and instrumentation. The system did not provide the high throughput capacity of automated EMIT but was much better than conventional TLC. The TOXI-LAB assay was reported to be successfully used as a screening method for urine samples or as a confirmatory technique to the immunoassays to minimize the need and cost of the GC-MS confirmation (M.J. Bogusz, 2008).
THC II THC II - A quick, easy, cost effective solution for screening or confirmation of the Marijuana Metabolite, THC-COOH in urine. Sensitivity of 15ng/mL for both screening and confirmation. Urine samples are hydrolysed and then acidified, centrifuged and aspirated through a SPEC-C18-1 column. The disc in the cartridge is then washed and dried and inoculated (Microgen Bioproducts). Figure 1 THC II
4.1 BACKGROUND The TOXI-LAB THC TLC drug detection system provides for extraction, concentration, inoculation, elution, and visualization steps for the detection of 9 -THC-COOH in urine specimens. The preliminary identification is based on matching the position of a drug (Rf) and visualization color characteristics with that of corresponding reference material.
4.2 SCOPE This method is an option to screen for the presence of 9 -THC-COOH in urine. TOXI- LAB THC II system provides a preliminary result that must be confirmed by GC-MSD.
4.3 SPECIMENS 4.3.1 The specimen volume is 2 mL for all specimen types except urine. The default volume for urine is 1 mL. 4.3.2 Specimens include whole blood, serum, plasma, urine, and tissue homogenate. 4.3.3 Dilutions of specimens may be analyzed at the Forensic Scientists discretion; however, this should be done in addition to testing the standard specimen volume, unless sample quantity dictates otherwise. 4.3.4 Analysis of larger specimen volumes must be approved and documented.
4.4 EQUIPMENT AND SUPPLIES 4.4.1 Tube rocker 4.4.2 Laboratory centrifuge 4.4.3 Solvent concentrator with appropriate concentration cups 4.4.4 Electric (plates) warmer 4.4.5 Fixed and adjustable volume single channel air displacement pipetters, and appropriate tips, capable of accurate and precise dispensing of volume indicated. 4.4.6 Forceps 4.4.7 Disc handing pins 4.4.8 Index cards for use as disc press cards 4.4.9 TOXI-GRAMS Blank THC-II-PLUS 4.4.10 TOXI-GRAMS Blank THC-II 4.4.11 TOXI-DISCS THC 4.4.12 SPEC-C18-1 extraction cartridges 4.4.13 THC II wash reagent 1 bottle
4.4.14 THC II wash reagent 2 bottle 4.4.15 TOXI-DIP THC-1 reagent tank with Lid 4.4.16 TOXI-DIP THC-2 reagent tank with Lid 4.4.17 HCl reagent tank with Lid 4.4.18 Chromatography tank with Lid (THC-II-PLUS) 4.4.19 Chromatography jar with Lid (THC-II) 4.4.20 TOXI-LAB THC elution solvent bottle
4.5 REAGENTS 4.5.1 11.8N KOH 4.5.2 Methanol 4.5.3 Wash reagent 1: 20% acetic acid 4.5.4 Wash reagent 2: 20% methylene chloride in n-Heptane 4.5.5 TOXI-DIP THC-1 Fast Blue BB: prepare with approximately 1g Fast Blue BB salt (purified grade). Add Fast Blue BB to reagent tank for TOXI-DIP THC-1. Add approximately 700mL methylene chloride. Solution should be pale yellow in color. Mix well. Store at room temperature. Solution stable for 2-3 months. 4.5.6 TOXI-DIP THC-2 Diethylamine (DEA) Fuming: pipet 40mL DEA through an opening in the standoff to the bottom of the tank. Remove any DEA on standoff surface. Store at room temperature. Replace DEA weekly. 4.5.7 HCl Fuming: pipet 40mL concentrated HCl through an opening in the standoff to the bottom of the tank. Remove any HCl on standoff surface. Store at room temperature. Replace HCl weekly. 4.5.8 THC II Stock Elution Solution: in the THC II Elution Solution bottle, mix 50mL n- heptane, 50mL acetone and 1mL glacial acetic acid. Cap tightly and mix. Store at room temperature.
4.6 REFERENCE MATERIAL
4.6.1 POSITIVE CONTROL Positive control can be prepared by adding specified amount of Working Control Solution to negative urine and/or obtained commercially. Use the same lot of negative urine to prepare positive control as used to prepare negative control.
4.6.1.1 Stock Reference Solution 100g/mL (+) 11-nor-9-carboxy- 9 -THC 4.6.1.2 Working Reference Solution (1800ng/mL) Add 900L Stock Solution to 49.1mL methanol. Solution is stable for six months when stored at 4C. 4.6.2 NEGATIVE CONTROL Negative urine: may be either in-house verified or commercially obtained.
4.7 PROCEDURE 4.7.1 INITIAL SET-UP Label extraction tubes and extraction cartridges for the negative contro, positive control, and appropriate laboratory numbers. 4.7.2 60ng/mL CARBOXY-THC POSITIVE CONTROL 4.7.2.1 Transfer 6mL of negative urine to extraction tube. Use the same lot of urine for negative control. 4.7.2.2 200L of working reference solution. Vortex. 4.7.3 NEGATIVE CONTROL Transfer 6mL of negative urine to extraction tube. 4.7.4 CASEWORK SAMPLE PREPARATION Transfer 6mL of casework urine specimen to extraction tube. 4.7.5 SAMPLE HYDROLYSIS 4.7.5.1 To 6mL of urine, add 12 drops 11.8N KOH. Vortex. 4.7.5.2 Allow to hydrolyze for 10 minutes. 4.7.5.3 Add 1.5mL glacial acetic acid. Vortex. 4.7.6 EXTRACTION 4.7.6.1 Condition cartridge with 1mL methanol. Aspirate at approximately 5 in. HG. Do not allow the disc to dry. 4.7.6.2 Add acidified samples to cartridge reservoirs. Aspirate such that the sample passes through the column no faster than 2mL/min. 4.7.6.3 Once the sample is completely through the reservoir, remove filter. 4.7.6.4 Add 1mL 20% acetic acid. Aspirate 2 min at 10-12 in. Hg. 4.7.6.5 Ass 500L wash reagent. Aspirate at 2 min at 10-12 in. Hg. 4.7.6.6 After solvent has past through, allow to aspirate 2 min.
4.7.6.7 Remove disc from cartridge and place into a pre heated concentrated cup to remove all residual moisture. 4.7.7 TLC 4.7.7.1 Place disc into labeled 3 or 10-channel TOXI-GRAM for THC-II. 4.7.7.2 Add THC-DISC THC disc. (if not all channels are used, remove excess with razor blade or scissors.) 4.7.7.3 Heat the GRAM, with the disc and slightly off the warmer edge, for 30-60 sec. 4.7.7.4 Add 12.5 mL of developing solution to chromatography tank (10 channel) or 3mL solution to chromatography jar (3 channel). 4.7.7.5 Place GRAM into chromatography tank or jar. Allow dye marker to migrate to almost 4cm. (this only take 2-3 min) 4.7.7.6 Remove GRAM from tank/jar and place face down on warmer for 1-2 min. 4.7.7.7 Dip GRAM into TOXI-DIP THC-I, hold to dry until GRAM become speckled. 4.7.7.8 Place GRAM into TOXI-DIP THC-II until scarlet spots develop. 4.7.7.9 Place GRAM in hood so that the DEA can evaporate. If any DEA is present when the HCl is added, fuming will occur. 4.7.7.10 For HCl fuming, either of the following options may be pursued. Option 2 will produce a more intense color which photocopies better. Option1: place GRAM into HCl fuming Tank until a purple spot develops. Place GRAM into page protector, label and photocopy. Option 2: place GRAM onto a page protector. With bulb pipet, add concentrated HCl to just cover GRAM. Note desired color change to deep purple. Label and photocopy GRAM. 4.7.7.11 Place a copy of GRAM into each associated casefile. 4.7.8 Detection and identification criteria The position (Rf) and color characteristics at each stage of visualization of a spot noted for a specimen must correspond to that of reference material (Quality Manager of Idaho State Police, 2008).
4.8 Drug Test Detection Times Drug tests detect not only drugs but metabolites as well. Metabolites are the byproducts of a substance after it has run through system. To determine whether a person will pass or not, it is important to know how much of the illicit metabolites are in urine, as well as the test cut off, or Level of Detection (LOD). Usually marijuana (cannabis or THC)
tests will have a cutoff of 50ng/mL, but it can be as low as 25ng/mL. Home testing can show whether a person level at the time of the test is above or below the 50ng/mL level, but it will not show the exact level of THC metabolites in system.
4.8.1 Marijuana Detection Time and Half-Life of TetraHydraCannabinol (THC) The half life of THC concentration is about 10 days. There is way too much variation to even approximate how long THC will be detected in the urine of an individual. Infrequent users with a fast metabolism will have the shortest detection time. Frequent or chronic users with a slow metabolism will have the longest detection times. The only way to estimate a detection time is to consider the lower and upper bounds (3-50 days), and estimate based on the factors outlined here. Marijuana Detection Time Based on Usage Usage at 1 time only 5-8 days Usage at 2-4 times per month 11-18 days Usage at 2-4 times per week 23-35 days Usage at 5-6 times per week 33-48 days Daily Usage 49-63 days Note: Detection times vary depending on many factors, including drug potency, tolerance, patients condition, fluid intake at time of test, method and frequency of marijuana use, body type, metabolism, exercise frequency and many others. These are general guidelines only. 4.8.2 How is a Positive Test Defined? 50 nanograms of THC metabolites per milliliter defines a presumptive positive by most laboratories and instant tests. This value was originally 20 ng/mL, but too many false positives resulted. So the level was raised to 100 ng/mL to reduce false positives. As of January 1995, the threshold was lowered back down to 50 ng/mL because it became known that drinking excessive water could easily bring the level of metabolites in the urine below 100 ng/mL. Some employers may use a lower cutoff, but that is rare. If a specimen screens non-negative for THC (anything other than negative or fails an integrity test), the specimen is then sent through a Gas Chromatograph/Mass Spectrometer (GC/MS) for the specific metabolite tripping the immunoassay screening. This level is set at 15 ng/m, and is used as the ultimate confirmation for a positive on drug test.
4.8.3 Can Second hand Smoke Cause a Positive Drug Test? In rare occurrences, second hand marijuana smoke can cause to fail drug test. It is possible that second hand marijuana smoke will raise someone to the 50 ng/mL level. However, extreme second hand exposure is required. For instance, being in a closed car full of pot smokers for several hours might cause someone to test positive in a drug test the very next day. Non-smokers are safe in a ventilated area such as an average living room or garage where partygoers are smoking pot.
4.8.4 What about Other Drugs? How Long Do They Stay In System? 50% of all drug test positives are for marijuana. What about the other 50%? The table below shows how long drugs other than marijuana typically stay in system: Urine Blood Hair Saliva Marijuana- Single Use 1-7 + days 12-24 hours Doubtful Not validated. Estimated 0-24 hours Marijuana Regular Use 7-100 days 2-7 days Months Amphetamines 1-3 days 24 hours Cocaine 1-3 days 1-3 days Heroin, Opiates 1-4 days 1-3 days PCP 3-7 days 1-3 days
The most popular kind of drug test is the urine test, which can detect marijuana for days or weeks after use. Note that urine tests do not detect the psychoactive component in marijuana, THC (delta-9-tetrahydrocannabinol), and therefore in no way measure impairment; rather, they detect the non-psychoactive marijuana metabolite THC-COOH, which can linger in the body for days and weeks with no impairing effects. Because of THC- COOH's unusually long elimination time, urine tests are more sensitive to marijuana than other commonly used drugs (California NORML Guide Interpreting Drug Test Results, 2012). Blood tests are a better detector of recent use, since they measure the active presence of THC in the system. Because they are invasive and difficult to administer, blood tests are used less frequently. They are typically used in investigations of accidents, injuries and DUIs,
where they can give a useful indication of whether the subject was actually under the influence (California NORML Guide Interpreting Drug Test Results, 2012). Hair tests are the most objectionable form of drug testing, since they do not measure current use, but rather non-psychoactive residues that remain in the hair for months afterwards. These residues are absorbed internally and do not appear in the hair until 7-10 days after first use. Afterwards, they cannot be washed out by shampoos (though shampoos may help remove external smoke particles that get stuck in the hair). Hair tests are more likely to detect regular than occasional marijuana use. One study found that 85% of daily users tested positive for marijuana, versus 52% of occasional smokers (1-5 times per week). Ingested cannabis was less likely to be detected than smoked marijuana. It is doubtful whether hair tests are sensitive to one-time use of marijuana (California NORML Guide Interpreting Drug Test Results, 2012). Saliva testing is a newer, less proven technology. The sensitivity of saliva tests is not well established in the case of marijuana. In theory, they are supposed to detect recent use, but this may range from several hours to over a day. They are supposed to detect secretions from inside the oral tissues that cannot be washed out with mouthwash. Because they are less intrusive than blood or urine tests, the industry has been eager to develop saliva tests. Due to reliability problems, they have yet to gain acceptance in the U.S., but they have come into use in some other countries, such as Australia. An international study of various onsite saliva tests concluded that no device was reliable enough to be recommended for roadside screening of drivers (California NORML Guide Interpreting Drug Test Results, 2012).
4.8.5 Why Choose Oral Fluid versus Urine Drug Testing? Oral fluid testing can detect drugs anytime, from immediately after the most recent use, up to three days after use. Conventional drug testing with urine cannot accurately detect usage in the first four hours after use, thus making saliva superior for post-accident testing (Forensic Fluids Laboratories, 2011).
4.8.6 Saliva THC VS Urine THC In general, what is in the blood, is in the saliva. If a drug is smoked, like THC, you may also find this in the mouth, thus giving a positive, saliva drug test. THC psychoactive effects are seen for 3 to 5 hours after normal drug use, although further effects, for longer periods, have been identified. Delta 9 THC, the parent, and 11 hydroxy 9 delta 9 THC, the metabolite, are the psychoactive compounds (Forensic Fluids Laboratories, 2011).
Saliva THC Delta 9 THC is the parent compound. When found in saliva, this means impairment, because the drug has entered the blood stream and affected the brain, thus affecting motor skills. Levels we have measured in saliva in the lab range from 0.5ng/mL to 150ng/mL (1 ng/mL = 1 part per billion). All of these mean the parent compound is available to the brain. The higher the level, the more drug ingested or the more recently the drug was used. Delta 9 THC has been measured up to 72 hours after smoking, in saliva (Forensic Fluids Laboratories, 2011). Urine THC 11 nor 9 carboxy THC is the major metabolite found in urine. A single dose of THC may be detected in urine for an average of 24 to 120 hours. In most peer reviewed papers, the highest doses produced positive screens for up to 120 hours, with most papers reporting an average of 26 to 33 hours. (These data are taken from over 80 peer reviewed papers). Urine excretion of THC does not decrease monotonously so urine screenings may fluctuate between negative and positive for a while (Forensic Fluids Laboratories, 2011).
5.0 IDENTIFICATION OF THC
In general, immunoassays (IA) are adopted as a preliminary test method in drug testing programs. However, false-positive (or false-negative) results occur from structurally related drugs that are recognized by the antibodies or occasionally by artefacts, such as adulterants affecting pH, detergents, and other surfactants. For this reason, any positive result must be confirmed by a Chromatographic technique, preferably with mass spectral identification. Gas chromatography and liquid chromatography coupled with mass spectrometry (GC/MS or LC/MS) are the gold standard procedures. In some previous studies, the window of detection for THC-COOH or cannabinoids in urine samples was demonstrated with ranges from several days in infrequent users to weeks or months in frequent users (Table 1).
6.0 ANALYSIS OF THC
Example Study: THC detection time in occasional marijuana smoker (using an immunochromatographic assay)
This document contains the results and specifics of a study designed to test THC metabolite detection time in urine. A primitive study was performed to determine the timeline of detectablity of ingested THC. It is generally purported that the ingestion of marijuana is detectable in urine for weeks or even months after ingestion. It has been reported that occasional users purge any detectable levels of THC from their system within 48-72 hours. It is widely accepted that other ingested illicit substances including Cocaine, Methamphetamine, and MDMA are not detectable after 24-48 hours of ingestion, thereby making THC the only illicit drug widely believe to be reliably tested for long term using a urinalysis. This study casts doubt on the validity of drug testing as a reliable means for determining ingestion of illicit substances at all due to the relatively short detection times of any drug. The study tested one subject using a common and readily available IC urinalysis(ICA) test. On day one(D1) an initial test was performed to ensure that the subject was free of detectable levels of THC. On day two(D2) the subjected ingested THC using the common procedure of smoking dried cannabis using a pipe. Approximately two 'bowls' were smoked
over the course of a day, and the subject ingested his last 'hit' at approximately 8pm on day two(D2). After the initial ingestion the subject abstained from any further contact with THC or marijuana for the duration of the study. No special cleansing products were used, no unusual amounts of liquids were consumed, and no adulterants were introduced into the specimen. The subject was then tested every day until the ICA(*1) tested negative (-) for detectable levels of THC(D4). The subject was then tested for one additional day(D5) to ensure the reliability of the previous test(D4). The subject is a 21 year old male 5'7' aprox. 145lbs - occasional marijuana smoker (~1/wk-1/mo) who prior to initial testing abstained from ingesting marijuana(THC) for approximately two weeks before the initial ICA(*1) urinalysis on which he tested negative(-).
IC Assay Overview: The ICA(*1) is a competitive binding immunoassay in which drug and drug metabolites in a urine sample compete with immobilized drug conjugate for limited labeled antibody binding sites. By utilizing antibodies that are specific to different drug classes, the test permits independent, simultaneous detection of two drugs from a single sample. The approximate run time is 5 minutes. In the assay procedure, urine mixes with labeled antibody-dye conjugate and migrates along a porous membrane. When the concentration of a given drug is below the detection limit of the test, unbound antibody-dye conjugate binds to antigen conjugate immobilized on the membrane, producing a rose-pink color band in the appropriate Test Zone for that drug. Conversely, when the drug level is at or above the detection limit, free drug competes with the immobilized antigen conjugate on the membrane by binding to antibody-dye conjugate, forming an antigen- antibody complex, preventing the development of a rose-pink color band. Regardless of the drug levels in the sample, a rose-pink color band is produced in each Control Zone (marked C) by a parallel immunochemical reaction. These bands serve as built-in quality control measures by demonstrating antibody recognition, verifying that the reagents are chemically active. Each ICA(*1) contains dye-conjugated antibody and immobilized antigen in protein matrix with sodium azide. The samples were tested by immersing the ICA(*1) test strips in the urine for ~10 seconds congruent with package labeling.
The test is a two panel test purported to detect at the NIDA cutoff levels: THC(tetrahydrocannabinol) at 50ng/ml METH(methamphetamine) at 500ng/ml.
The ICA(*1) consisted of two panels, one that tested for the presence of METH, and one for the presence of THC. Each panel had two lines, the first line being the metabolite detection line, the second line being the urine detection line. The second line alerts you to the fact that the urine has in fact passed over the metabolite detection line, allowing you to determine that the sample has traveled over the metabolite detection line and has in fact been tested. A positive detection of THC was determined by the lack of a detection line. A negative detection of THC was determined by the presence of a detection line. According to the package, the width and opacity of the detection lines indicate nothing about the intherent presence of THC or METH in the urine, though we found on day three a slight presence of a detection line, it was still determined to be a failing test, as the line was so faint as to be inconsequential. It was noted that the on THC panel the urine detection and THC detection lines were consistently lighter than the METH panel lines.
Study Analysis: Days on which tests are passed are denoted by color, green is a passing test, red is a failed test. Day One (Thursday) (D1): Initial test to determine passing levels of THC in the urine. Day Two (Friday) (D2): Day of ingestion Day Three (Saturday) (D3): T+24 Day Four (Sunday) (D4): First Passing Day, approximately two days (48 hours) after initial ingestion Day Five (Monday) (D5): Consistent with the previous day, the subject passed the ICA(*1) test. Study Summary: The study showed that in an occasional marijuana smoker that detection times for THC are approximately 24 hours, within 48 hours of ingestion the subject was testing clean (-) Detection times were determined to be so short that it would be possible to ingest THC on a
friday and be clean by monday, thereby negating any test given after 48 hours of initial ingestion.
Figure: THC detection urine tests
Reference California NORML Guide Interpreting Drug Test Results, 2012. Drug Test Detection. Available online at: http://www.canorml.org/healthfacts/drugtestguide/drugtest detection.html. Accessed on November 4, 2013.
Forensic Fluids Laboratories, 2011. Oral Fluid vs. Urine Drug Testing. Available online at: http://www.forensicfluids.com/oral_v_urine.htm. Accessed on November 4, 2013.
Microgen Bioproducts. Toxicology. Available online at: http://www.microgenbioproduct s.com/pdf/Product%20Brochures_Individual/Toxilab.pdf. Accessed on November 4, 2013.
Marijuana. Drug Test Detection Times. Available online at: http://www.marijuana.com/ news/drug-test/detection-time/. Accessed on November 4, 2013.
ProCog.org, 2013. Pharmaceutical Drugs Based on Cannabis. Available at: http://medical marijuana.procon.org/view.resource.php?resourceID=000883.Accessed on November 4, 2013.
Quality Manager of Idaho State Police, 2008. Urine Toxicology. Available online at: http://www.isp.idaho.gov/forensics/documents/archivedAMs/Toxicology/2.2.4%20T OXI-LAB%20c-THC%20rev%205.pdf. Accessed on November 4, 2013.
Development and Application of A LC-MS/MS Method For The Analysis of Plasma Bioavailabilities of Different Cannabinoids After The Administration of Cannabis Sativa L. Extracts and MarinolTM